Protokinetix, Inc. (PKTX) — SEC Filings
Protokinetix, Inc. (PKTX) — 14 SEC filings. Latest: 8-K (Nov 21, 2025). Includes 6 10-Q, 3 8-K, 2 10-K.
View Protokinetix, Inc. on SEC EDGAR
Overview
Protokinetix, Inc. (PKTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K/A filed on Nov 19, 2025: ProtoKinetix, Inc. filed an 8-K/A amendment on November 19, 2025, to correct the contact number in its original filing and to include a revised press release dated November 17, 2025. The amendment clarifies information previously submitted regarding Regulation FD Disclosure and Financial Statements
Sentiment Summary
Across 14 filings, the sentiment breakdown is: 3 bearish, 11 neutral. The dominant filing sentiment for Protokinetix, Inc. is neutral.
Filing Type Overview
Protokinetix, Inc. (PKTX) has filed 3 8-K, 1 8-K/A, 6 10-Q, 1 DEF 14A, 2 10-K, 1 SC 13D/A with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (14)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 21, 2025 | 8-K | 8-K Filing | |
| Nov 19, 2025 | 8-K/A | ProtoKinetix Files 8-K/A Amendment for Contact Correction | low |
| Nov 17, 2025 | 8-K | 8-K Filing | |
| Nov 13, 2025 | 10-Q | ProtoKinetix Deepens Losses Amidst Continued R&D Spending | high |
| Oct 10, 2025 | 8-K | ProtoKinetix Files 8-K with Corporate Updates | low |
| Sep 15, 2025 | DEF 14A | ProtoKinetix Seeks 20% Stock Authorization Hike to Avert Liquidation | high |
| Aug 13, 2025 | 10-Q | ProtoKinetix's Losses Mount Amidst Ongoing Research, Cash Infusion | high |
| May 15, 2025 | 10-Q | ProtoKinetix Files Q1 2025 10-Q | low |
| Mar 28, 2025 | 10-K | ProtoKinetix Files 2024 10-K | low |
| Nov 12, 2024 | 10-Q | ProtoKinetix Files Q3 2024 10-Q | low |
| Jul 30, 2024 | 10-Q | ProtoKinetix, Inc. Files 10-Q for Q2 2024 | low |
| Jun 17, 2024 | SC 13D/A | Smith Amends ProtoKinetix Stake Filing | medium |
| May 15, 2024 | 10-Q | ProtoKinetix, Inc. Files 10-Q for Period Ending March 31, 2024 | low |
| Mar 20, 2024 | 10-K | ProtoKinetix, Inc. Files 2023 Annual Report on Form 10-K | low |
Risk Profile
Risk Assessment: Of PKTX's 12 recent filings, 3 were flagged as high-risk, 1 as medium-risk, and 8 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $ (273,662) |
| EPS | $ (0.00) |
| Debt-to-Equity | 0.91 |
| Cash Position | $ 607 |
| Operating Margin | N/A |
| Total Assets | $ 477,623 |
| Total Debt | $ 227,196 |
Key Executives
- Grant Young
- Clarence E. Smith
- Michael R. Guzzetta
- Edward P. McDonough
- Alexandra Smith
- John & Edith Smith
Industry Context
ProtoKinetix operates in the highly competitive and capital-intensive biotechnology and medical research sector. Companies in this space typically face long development cycles, significant regulatory hurdles, and a high risk of failure. Success often depends on groundbreaking research, securing substantial funding, and navigating complex intellectual property landscapes.
Top Tags
10-Q (4) · pharmaceuticals (4) · amendment (2) · Biotechnology (2) · Development Stage Company (2) · Going Concern (2) · Net Loss (2) · Equity Financing (2) · quarterly-report (2) · 10-K (2)
Executive Compensation
From the most recent DEF 14A filing (Sep 15, 2025):
- Clarence E. Smith — Chairman, Chief Executive Officer, President: $N/A
- Michael R. Guzzetta — Chief Financial Officer: $N/A
- Edward P. McDonough — Director: $N/A
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $273,662 | Increased from $261,676 in the prior year, indicating growing operational costs without revenue. |
| Accumulated Deficit | $48,501,809 | Highlights the company's long history of losses and lack of profitability since inception. |
| Cash on Hand | $607 | Extremely low cash balance, underscoring the immediate need for additional financing. |
| Cash from Financing Activities | $177,500 | Primary source of cash inflow, demonstrating reliance on equity dilution for operations. |
| Intangible Assets | $475,966 | Represents the majority of the company's assets, primarily patent application rights, with no current revenue generation. |
| Common Shares Outstanding | 390,080,152 | Increased from 371,880,152 at December 31, 2024, indicating significant share dilution. |
| Research and Development Expenses | $82,392 | Increased from $78,625 in the prior year, reflecting ongoing investment in AAGP research. |
| Professional Fees | $107,991 | Increased from $98,647 in the prior year, contributing to higher operating expenses. |
| Current authorized common stock shares | 500,000,000 | Proposed to be increased to 600,000,000 |
| Proposed authorized common stock shares | 600,000,000 | Represents a 20% increase from current authorization |
| Shares of common stock outstanding | 389,080,152 | As of the September 5, 2025 Record Date |
| Shares underlying outstanding options | 94,790,000 | Reduces available shares for issuance |
| Shares underlying outstanding warrants | 8,600,000 | Reduces available shares for issuance |
| Shares available for issuance | 1,529,848 | Extremely limited, necessitating the increase in authorized shares |
| Record Date | 2025-09-05 | For determining stockholders entitled to submit written consents |
Frequently Asked Questions
What are the latest SEC filings for Protokinetix, Inc. (PKTX)?
Protokinetix, Inc. has 14 recent SEC filings from Mar 2024 to Nov 2025, including 6 10-Q, 3 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PKTX filings?
Across 14 filings, the sentiment breakdown is: 3 bearish, 11 neutral. The dominant sentiment is neutral.
Where can I find Protokinetix, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Protokinetix, Inc. (PKTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Protokinetix, Inc.?
Key financial highlights from Protokinetix, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PKTX?
The investment thesis for PKTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Protokinetix, Inc.?
Key executives identified across Protokinetix, Inc.'s filings include Grant Young, Clarence E. Smith, Michael R. Guzzetta, Edward P. McDonough, Alexandra Smith and 1 others.
What are the main risk factors for Protokinetix, Inc. stock?
Of PKTX's 12 assessed filings, 3 were flagged high-risk, 1 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Protokinetix, Inc.?
Forward guidance and predictions for Protokinetix, Inc. are extracted from SEC filings as they are enriched.